A5028408099- Cervical Cancer and HPV Research
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Genital Health and Disease
- Global Cancer Incidence and Screening
- Cancer-related gene regulation
- Reproductive tract infections research
- Molecular Biology Techniques and Applications
- MicroRNA in disease regulation
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
Amsterdam University Medical Centers
2018-2021
Vrije Universiteit Amsterdam
2018-2021
Amsterdam UMC Location Vrije Universiteit Amsterdam
2014-2018
Zero to Three
2015
Abstract Primary testing for human papillomavirus (HPV) in cervical screening requires triage to differentiate women with transient infection from those persistent who require more intensive management given their risk (pre)cancer. In this study, the clinical performance of a novel methylation marker FAM19A4 high-risk (hr)HPV-positive was evaluated. Using training-validation set approach, we analyzed quantitative methylation-specific PCR (qMSP). The training comprised hrHPV-positive scrapes...
DNA methylation analysis of cancer-related genes is a promising tool for HPV-positive women to identify those with cervical (pre)cancer (CIN3+) in need treatment. However, clinical performance markers can be influenced by the sample type utilized. We describe multiplex quantitative methylation-specific PCR that targets FAM19A4 and mir124-2 loci, detect CIN3+ using both lavage- brush self-samples.We determined thresholds classification training sets comprising lavage self-samples 182...
Aims Gene promoter hypermethylation is recognised as an essential early step in carcinogenesis, indicating important application areas for DNA methylation analysis cancer detection. The current study was set out to assess the performance of CADM1 , MAL and miR124- 2 cervical scrapes detection endometrial cancer. Methods A series women with (n=79) or (n=21) cancer, intraepithelial neoplasia grade 3 (CIN3) (n=16) CIN2 (n=32), without evidence worse (n=120) were assessed miR124-2 . Methylation...
DNA methylation analysis of cervical scrapes using FAM19A4 and mir124‐2 genes has shown a good clinical performance in detecting cancer advanced CIN lesions need treatment HPV‐positive women. To date, longitudinal data on the risk test‐negative women are lacking. In our study, we assessed outcome FAM19A4/mir124‐2 an screening cohort with 14 years follow‐up. Archived 1,040 (age 29–61 years), who were enrolled POBASCAM trial (ISRCTN20781131) tested for / methylation. By linkage nationwide...
Purpose: Epigenetic host cell changes involved in cervical cancer development following a persistent high-risk human papillomavirus (hrHPV) infection, provide promising markers for the management of hrHPV-positive women. In particular, based on DNA methylation tumor suppressor gene promoters are valuable. These ideally identify women with precancer (CIN2/3) need treatment. Here, we set out to biologically relevant by genome-wide analysis both hrHPV-transformed lines and tissue...
Recently, DNA methylation analysis of FAM19A4 in cervical scrapes has been shown to adequately detect high‐grade intraepithelial neoplasia and cancer (≥CIN3) high‐risk HPV (hrHPV)‐positive women. Here, we compared the clinical performance cytology HPV16/18 genotyping, separately combination, for ≥CIN3 detection hrHPV‐positive women participating a prospective observational multi‐center cohort study. The study population comprised aged 18–66 years, visiting gynecological outpatient clinic....
High-risk human papillomavirus (hrHPV)-positive women require triage to identify those with cervical high-grade intraepithelial neoplasia and cancer (⩾CIN3 (cervical grade 3)). FAM19A4 methylation analysis, which detects advanced CIN cancer, is applicable different sample types. However, studies comparing the performance of analysis in hrHPV-positive self-samples paired physician-taken scrapes are lacking. We compared (and/or HPV16/18 genotyping) for ⩾CIN3 detection (n=450,18–66 years)....
Abstract Primary screening for high-risk human papillomavirus (hrHPV) requires a triage protocol. Repeat cytology testing at baseline and after 6 to 12 months has emerged as reasonable approach, but carries the risk of loss follow-up. may be omitted if is supplemented with another, complementary test baseline. In this study, performance combined by DNA methylation analysis was assessed. hrHPV-positive cervical scrapes (n = 250), [threshold: atypical squamous cells undetermined significance...
High-grade cervical intraepithelial neoplasia (CIN2 and CIN3) represents a heterogeneous disease with varying cancer progression risks. Biomarkers indicative for productive human papillomavirus (HPV) infection (HPV E4) transforming HPV (p16ink4a , Ki-67 host-cell DNA methylation) could provide guidance clinical management in women high-grade CIN. This study evaluates the cumulative score of immunohistochemical expression p16ink4a (Scores 0-3) 0-3), referred to as "immunoscore" (IS), 262 CIN2...
Cervical cancer is the leading cause of cancer-related death in women South Africa. This study evaluates DNA methylation levels cervical (pre)cancer and aims to assess value high-risk human papillomavirus (hrHPV) testing analysis, alone or combination, on physician-taken scrapes detect cancer, intraepithelial neoplasia grade 3 (CIN3) an HIV-infected African population.Prospective observational multicentre cohort study.Women from a living with HIV (n = 355) referral 109, 60% seropositive)...
Cervical screening by high-risk HPV (hrHPV) testing requires additional risk stratification (triage), as most infections are transient and only a subset of hrHPV-positive women harbours clinically relevant disease. Molecular triage markers such microRNAs (miRNAs) DNA methylation particularly promising, they can be objectively tested directly on scrapes cervicovaginal self-samples. Here, we evaluated the marker potential 10 candidate miRNAs in 209 with underlying precancer (cervical...
<p>Figure S1: Overview of MSP results in Verification II. Figure S2: Representative cervical tissue specimens. S3: Validation GHSR, SST and ZIC1 by qMSP hrHPV-positive scrapes. S4: No association FAM19A4, CADM1, MAL miR124-2 methylation levels with 3q gain. Table Number samples used per study item.</p>
<div>Abstract<p><b>Purpose:</b> Epigenetic host cell changes involved in cervical cancer development following a persistent high-risk human papillomavirus (hrHPV) infection, provide promising markers for the management of hrHPV-positive women. In particular, based on DNA methylation tumor suppressor gene promoters are valuable. These ideally identify women with precancer (CIN2/3) need treatment. Here, we set out to biologically relevant by genome-wide analysis both...
<div>Abstract<p><b>Purpose:</b> Epigenetic host cell changes involved in cervical cancer development following a persistent high-risk human papillomavirus (hrHPV) infection, provide promising markers for the management of hrHPV-positive women. In particular, based on DNA methylation tumor suppressor gene promoters are valuable. These ideally identify women with precancer (CIN2/3) need treatment. Here, we set out to biologically relevant by genome-wide analysis both...
<p>Figure S1: Overview of MSP results in Verification II. Figure S2: Representative cervical tissue specimens. S3: Validation GHSR, SST and ZIC1 by qMSP hrHPV-positive scrapes. S4: No association FAM19A4, CADM1, MAL miR124-2 methylation levels with 3q gain. Table Number samples used per study item.</p>